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physicians $3.2 billion (95% CI: $2.88–$3.49 billion) in 2006.
CONCLUSION: Medicaid PDLs for statins and antihyperten-
sives have generated considerable costs for physicians. Physicians
would incur substantial additional costs if Medicare adopted
similarly-structured PDLs for Part D.
PODIUM SESSION I: WOMEN’S HEALTH
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OBJECTIVES: To determine the predictors of breast cancer
patients’ (BCPs) willingness to accept local and systemic therapy.
METHODS: Cross-sectional survey of BCPs ages 36–80 at the
University of Maryland Greenebaum Cancer Center, Baltimore,
MD. Since “treatment” is considered a “short-term” health state,
the chained procedure for the time trade-off (TTO) was used to
assess TTO. Willingness to accept therapy was determined using
“minimum cancer-free years to accept therapy” (CFYs) as the
dependent variable. The number of CFYs was calculated based
upon BCPs TTO responses for mastectomy (MRM), breast-con-
serving therapy (BCT), chemotherapy (CTX) and tamoxifen
(TAM). Demographic and clinical data were abstracted from
medical records. Tobit regression models were used for multi-
variate analyses. RESULTS: Mean age = 56.0 years (SD ± 9.43,
n = 77); 58.2% were white; 75.6% had early stage cancer. BCPs
required more CFYs (median = 4) to accept MRM than to accept
BCT, CTX, or TAM (median 1 year for each). For all forms of
therapy, the mode = 0, suggesting that BCPs were willing to
accept therapy even if it provided no additional CFYs. Late stage
patients required more CFYs to accept TAM (β = 6.61, p =
0.0489); similarly late stage patients in good physical health
required more CFYs to have MRM (β = 0.50, p = 0.0322). Treat-
ment-experienced BCPs were more willing to accept that type of
therapy than those who were treatment-naïve. Younger patients
(<65) required fewer CFYs to accept chemotherapy (age group
50–54, β = −4.77, p = 0.0403; 55–59, β = −7.25, p = 0.0019).
Being non-white and having less education were associated with
requiring fewer CFYs to accept to accept CTX (β = −3.86, p =
0.0087; β = −5.10, p = 0.0193, respectively). CONCLUSION:
BCPs required relatively few CFYs to accept treatment. Willing-
ness-to-accept fewer CFYs for CTX among those with less edu-
cation and of younger age is consistent with treatment patterns
previously-published. The fact that non-whites (primarily
African Americans) required fewer CFYs to accept CTX appears
in contrast to observed underutilization of CTX among African
American BCPs.
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OBJECTIVES: To assess women’s preferences/utilities for health
states speciﬁc to advanced stage breast cancer including baseline
diagnoses of advanced stage breast cancer (ABC), treatment
response, no treatment response, disease progression and espe-
cially their point of indifference between treatment-related toxi-
cities and treatment response. METHODS: FACT-B QOL data
from patients with ABC were used to compose health narratives
consisting of physical, social, emotional, functional well-being,
additional concerns content domains. Toxicities were described
separately. 100 peri/post menopausal women were interviewed
by a woman using Visual Analogue (VA) standard gamble tech-
niques (SG). Baseline ABC, treatment response, no treatment
response and disease progression were conducted using SG as
usual with oscillating risks of perfect health (1) and immediate
death (0) as anchors OR the HS narrative with 100% certainty.
For toxicity, however, the true trade-off is treatment response
with an associated risk of toxicity OR no treatment and remain-
ing with 100% certainty at baseline ABC. This allows one to
measure how much chance of response a woman needs to be
indifferent to the corresponding chance of toxicity. RESULTS:
Mean age was 55.76, 64% were postmenopausal, 11% had
breast cancer while 16% had another type of cancer previously.
VAS scores were 51.8 (p < 0.01) for baseline ABC, 82.5 (p <
0.01) for response, 57.5 (p < 0.01) for no response and 38.4 (p
< 0.01) for disease progression. SG regression results were 0.64
(p < 0.01) for baseline, 0.76 (p < 0.01) for treatment response,
0.67 (p < 0.01) for no response, and 0.50 (p < 0.01) for disease
progression. The trade-off between a chance of response with a
corresponding chance of toxicity yielded a value of 0.34 (p <
0.01) or utility score of 0.66 (p < 0.01). CONCLUSION: Women
need at least a 34% chance of treatment response to be indif-
ferent to treatment-related toxicity. These measured values are
more appropriate for Quality-adjusted Time Without Symptoms
of disease and Toxicity (Q-TWiST) analysis to value oncology
treatment.
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OBJECTIVES: To determine whether vasomotor symptom
reduction is associated with improved work productivity using
pooled data from 2 clinical trials for the relief of menopausal hot
ﬂushes with desvenlafaxine succinate (DVS). METHODS: A
total of 843 postmenopausal women experiencing 50 or more
moderate-to-severe hot ﬂushes per week received 100 or 150 mg/
day DVS or placebo in 2 randomized, double-blind, placebo-
controlled trials. Subjects kept daily hot ﬂush and sleep diaries
and completed the Proﬁle of Mood States (POMS) and Work
Limitations Questionnaire (WLQ) at baseline and week 12. To
control for multiplicity, the data were analyzed using multivari-
ate analysis of covariance (MANCOVA), adjusting for age, race,
type of menopause, and baseline values. RESULTS: At both 100-
and 150-mg doses, DVS reduced the number and severity of hot
ﬂushes from baseline to week 12 compared with placebo (all
comparisons, P < 0.0001). DVS reduced the number of night-
time awakenings due to hot ﬂushes (P < 0.0001) and improved
self-perceived sleep quality (P < 0.05) at both doses compared
with placebo. The 100 mg dose also signiﬁcantly increased the
daily number of minutes slept (P < 0.05). POMS total mood dis-
turbance score improved signiﬁcantly in both DVS dose groups
compared with placebo (P < 0.001). Work limitation, measured
by WLQ total index score, decreased signiﬁcantly from baseline
to week 12 in subjects treated with 100 mg DVS (adjusted mean
[SE] reduction = −3.3 [0.9]; P = 0.0115) compared with placebo
(−1.4 [0.9]). The 100 -mg dose group had signiﬁcant improve-
ment on the time management (P = 0.0354), mental-interper-
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sonal (P = 0.0034), and output demand (P = 0.0174) subscales.
For the 150-mg group, the reduction in WLQ total index score
approached signiﬁcance (−2.9 [0.9]; P = 0.0545) and the mental-
interpersonal improved signiﬁcantly compared with placebo (P
= 0.0057). CONCLUSION: Reductions in hot ﬂush frequency
and severity and improved sleep and mood are accompanied by
signiﬁcant improvement in work productivity in postmenopausal
women treated with DVS.
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OBJECTIVES: To evaluate the cost-effectiveness and budget
impact of vaccinating a single birth cohort of girls 11 years of
age with Gardasil, a novel vaccine against human papilloma
virus (HPV), in the presence of the current triennial cervical
screening programme. METHODS: A lifetime Markov model of
the incidence and prevalence of cervical dysplasia and cancer was
constructed from New Zealand cervical cancer registrations and
ﬁve-year survival plus the incidence of dysplasia estimated from
analyses of screening histories of 28,000 women. Costs of dys-
plasia, cervical cancer and genital warts were obtained from local
sources and health state utilities were taken from published
sources. Efﬁcacy was taken from several recent phase III clinical
trials (FUTURE). The model was internally validated against the
prevalence of dysplasia. RESULTS: Assuming lifetime protection
and 79% uptake of 3 doses, HPV vaccination would prevent 140
cervical cancer cases and 42 deaths over the lifetime of the vac-
cinated cohort. At a unit vaccine price per dose of $NZ128.50
and 5% annual discount rate, the cost per QALY in the base case
analysis is less than $NZ25,000 from either a health care or a
Government perspective. The annual budget impact of vaccina-
tion for the Government is $NZ10.5M. Catch-up vaccination
strategies for women age 12 to 26 y are more cost effective. These
ﬁndings are sensitive to the reduction in quality of life that
accompanies abnormal cytology or histology ﬁndings; vaccine
efﬁcacy; HPV genotype distribution; vaccine uptake and 
duration of protection. CONCLUSION: When a universal 
programme of HPV vaccination is added to current clinical
screening and management of dysplasia and cervical cancer, over
the lifetime of a birth cohort the cost required to provide each
additional quality adjusted life year is very modest by interna-
tional standards.
PODIUM SESSION II: MEDICATION ADHERENCE &
OUTCOMES
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OBJECTIVES: To examine the incidence of statin initiation in
patients with type 2 diabetes, medication compliance rates for
both antidiabetic and statin therapies, and the impact of patient
medication behavior on disease outcomes. METHODS: The Cal-
ifornia Medicaid program (Medi-Cal) claims data collected
during the period of January 1995 to December 2004 was ana-
lyzed. A total of 4222 patients with type 2 diabetes were included
in the study. Medication compliance was measured using Pro-
portion of Days Covered (PDC) in each quarter of the study
period. Descriptive analyses were performed to: 1) examine ini-
tiation of statin therapy and its change over time; and 2) compare
long-term medication compliance to statin and to antidiabetic
agents. A marginal structural model was employed to examine
the impact of medication compliance to statin therapy on car-
diovascular events. The effects of compliance on hospitalization
and total medical costs were estimated by generalized estimating
equations (GEE). RESULTS: Statin therapy was initiated by
2.71% of diabetic patients in 1996, rising to 18.08% in 2003.
Medication compliance to statin therapy was high (PDC = 0.83,
SD = 0.234) during the ﬁrst quarter of statin treatment. However,
patient compliance dropped sharply from the second quarter
(PDC = 0.63, SD = 0.382) and the medication compliance at the
end of the ﬁrst year of the treatment was decreased to 0.56. Over
the 30 quarters, patients were less likely to comply with statin
therapy than with antidiabetic treatment (approximately 35%
difference). Hispanic patients and patients with complicated
medication regimens were more likely to exhibit poor compli-
ance to statin therapy. Poor compliance to statin therapy was sig-
niﬁcantly associated with increased cardiovascular risk events (p
< 0.01) and hospitalization in patients with type 2 diabetes (p <
0.01). CONCLUSION: Prescribing of statins in diabetic popu-
lations has improved in recent years, but long-term medication
compliance to statin therapy and antidiabetic medications in the
California Medicaid population remains problematic.
AO2
THE ASSOCIATION BETWEEN THERAPEUTIC PERSISTENCE
AND NON-PHARMACY COST AMONG ANTI-TUMOR
NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF
RHEUMATOID ARTHRITIS
Tang B1,Thompson H1, Meissner BL2, Dabbous O1, Rahman M1
1Centocor, Inc, Horsham, PA, USA, 2Xcenda, Palm Harbor, FL, USA
OBJECTIVES: To evaluate the impact of persistence with anti-
TNF treatment on rheumatoid arthritis (RA)-related health care
costs among RA patients. METHODS: A retrospective study, 
utilizing the PharMetrics managed-care claims database, was
conducted. The ﬁrst anti-TNF (inﬂiximab, etanercept, or adali-
mumab) plus methotrexate encounter among RA patients
between January 1, 2001 and January 1, 2004 was identiﬁed.
Patients were required to have a minimum of 12-months of con-
tinuous plan eligibility prior to and following their index bio-
logic date. Persistence (%) was deﬁned as the number of days
between their ﬁrst biologic prescription and the last biologic
encounter, divided by 365 and multiplied by 100. Two mutually
exclusive cohorts were developed based on their level of anti-
TNF persistence: individuals who were persistent ≥80%; and
those who were persistent <80%. RA-related costs were com-
pared between two groups. RESULTS: A total of 1242 patients
were included, 339 patients (27.3%) with a persistency ratio
<80% and 903 (72.7%) patients with a persistency ratio ≥80%.
Over two-thirds of the patients were females and the mean age
was 50 years. Other than pharmacy cost, higher persistence
resulted in lower non-pharmacy medical costs ($3091 versus
$4601). The higher persistence cohort had signiﬁcantly lower
cost in all non-pharmacy cost categories: inpatient services,
physician services, other out-patient services, emergency room,
and lab costs as compared to the lower persistence cohort. After
adjusting for confounding variables (age, gender, co-morbidity,
and disease staging), patients in the higher persistence group 
had a signiﬁcant lower non-pharmacy cost with a lower co-
morbidity. There was no difference in age, gender, and disease
staging between the groups. CONCLUSION: This study indi-
cates that while higher pharmacy costs were associated with
